Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Oct;66(4):782–791. doi: 10.1172/JCI109916

Demonstration of a lack of change in serum 1 alpha,25-dihydroxyvitamin D in response to parathyroid extract in pseudohypoparathyroidism.

P W Lambert, B W Hollis, N H Bell, S Epstein
PMCID: PMC371653  PMID: 7419719

Abstract

Studies were carried out to compare the effects of parathyroid extract (PTE) on serum and urinary calcium (Ca) and phosphorus (P), serum 25-hydroxyvitamin D (25-OHD), serum 24,25-dihydroxyvitamin D (24,25(OH)2D), serum 1 alpha,25-dihydroxyvitamin D (1 alpha,25(OH)2D), and urinary cyclic AMP in two normal subjects, two patients with hypoparathyroidism (HP) and six patients with pseudohypoparathyroidism (PHP), some of whom were on suboptimal treatment with vitamin D. Two of the patients with PHP were studied while on long-term treatment with 1 alpha,25-(OH)2D3. Before PTE, serum 1 alpha, 25(OH)2D was at the lower limit of normal in one patient and was abnormally low in the other five patients. None of these individuals was on treatment with 1 alpha,25(OH)2D3. Serum 25-OHD and 24,25(OH)2D were either increased or at the upper limit of normal in the patients given vitamin D and were normal in the other patients. PTE lowered the serum P and increased the serum 1 alpha,25(OH)2D, serum and urinary Ca, urinary P, and urinary cyclic AMP in the normal subjects and patients with HP. In individual studies, changes in serum 1 alpha,25(OH)2D and serum Ca occurred in parallel before, during, and after PTE. In contrast, PTE had very little effect in the patients with PHP. Whereas there were highly significant positive correlations between serum 1 alpha,25(OH)2D in each of the normal subjects and patients with HP, there were significant correlations in only one of the patients with PHP. An increase in serum Ca in response to PTE was observed in one of the two patients with PHP who were on long-term treatment with 1 alpha,25(OH)2D3. In these individuals, PTE produced only slight increases in serum 1 alpha,25(OH)2D. Serum 25-OHD and 24,25(OH)2D were not changed by PTE in any of the subjects or patients. The results provide evidence that hypocalcemia in HP and PHP arises in part from low circulating 1 alpha,25-(OH)2D, and indicate that the lack of change in serum 1 alpha,25(OH)2D with PTE in patients with PHP is related to impaired renal adenylate cyclase and phosphaturic responses. These and previous results support the idea that diminished renal production of 1 alpha,25(OH)2D, because of a defect in the parathyroid hormone-responsive adenylate cyclase system, may be a contributing factor in the pathogenesis of the abnormal calcium metabolism in PHP.

Full text

PDF
782

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BELL N. H., GERARD E. S., BARTTER F. C. PSEUDOHYPOPARATHYROIDISM WITH OSTEITIS FIBROSA CYSTICA AND IMPAIRED ABSORPTION OF CALCIUM. J Clin Endocrinol Metab. 1963 Aug;23:759–762. doi: 10.1210/jcem-23-8-759. [DOI] [PubMed] [Google Scholar]
  2. Bell N. H., Avery S., Sinha T., Clark C. M., Jr, Allen D. O., Johnston C., Jr Effects of dibutyryl cyclic adenosine 3',5'-monophosphate and parathyroid extract on calcium and phosphorus metabolism in hypoparathyroidism and pseudohypoparathyroidism. J Clin Invest. 1972 Apr;51(4):816–823. doi: 10.1172/JCI106876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bell N. H., Stern P. H. Hypercalcemia and increases in serum hormone value during prolonged administration of 1alpha,25-dihydroxyvitamin D. N Engl J Med. 1978 Jun 1;298(22):1241–1243. doi: 10.1056/NEJM197806012982206. [DOI] [PubMed] [Google Scholar]
  4. Bone H. G., 3rd, Zerwekh J. E., Haussler M. R., Pak C. Y. Effect of parathyroidectomy on serum 1 alpha,25-dihydroxyvitamin D and intestinal calcium absorption in primary hyperparathyroidism. J Clin Endocrinol Metab. 1979 May;48(5):877–879. doi: 10.1210/jcem-48-5-877. [DOI] [PubMed] [Google Scholar]
  5. CORVILAIN J., ABRAMOW M. EFFECT OF GROWTH HORMONE ON TUBULAR TRANSPORT OF PHOSPHATE IN NORMAL AND PARATHYROIDECTOMIZED DOGS. J Clin Invest. 1964 Aug;43:1608–1612. doi: 10.1172/JCI105036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Caldas A. E., Gray R. W., Lemann J., Jr The simultaneous measurement of vitamin D metabolites in plasma: studies in healthy adults and in patients with calcium nephrolithiasis. J Lab Clin Med. 1978 May;91(5):840–849. [PubMed] [Google Scholar]
  7. Chase L. R., Melson G. L., Aurbach G. D. Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone. J Clin Invest. 1969 Oct;48(10):1832–1844. doi: 10.1172/JCI106149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Connerty H. V., Briggs A. R. Determination of serum calcium by means of orthocresolphthalein complexone. Am J Clin Pathol. 1966 Mar;45(3):290–296. doi: 10.1093/ajcp/45.3.290. [DOI] [PubMed] [Google Scholar]
  9. Drezner M. K., Burch W. M., Jr Altered activity of the nucleotide regulatory site in the parathyroid hormone-sensitive adenylate cyclase from the renal cortex of a patient with pseudohypoparathyroidism. J Clin Invest. 1978 Dec;62(6):1222–1227. doi: 10.1172/JCI109242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Drezner M. K., Neelon F. A., Haussler M., McPherson H. T., Lebovitz H. E. 1,25-Dihydroxycholecalciferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism. J Clin Endocrinol Metab. 1976 Apr;42(4):621–628. doi: 10.1210/jcem-42-4-621. [DOI] [PubMed] [Google Scholar]
  11. Farfel Z., Brickman A. S., Kaslow H. R., Brothers V. M., Bourne H. R. Defect of receptor-cyclase coupling protein in psudohypoparathyroidism. N Engl J Med. 1980 Jul 31;303(5):237–242. doi: 10.1056/NEJM198007313030501. [DOI] [PubMed] [Google Scholar]
  12. Finkelstein J. W., Roffwarg H. P., Boyar R. M., Kream J., Hellman L. Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab. 1972 Nov;35(5):665–670. doi: 10.1210/jcem-35-5-665. [DOI] [PubMed] [Google Scholar]
  13. Gallagher J. C., Riggs B. L., Eisman J., Hamstra A., Arnaud S. B., DeLuca H. F. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest. 1979 Sep;64(3):729–736. doi: 10.1172/JCI109516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gertner J. M., Horst R. L., Broadus A. E., Rasmussen H., Genel M. Parathyroid function and vitamin D metabolism during human growth hormone replacement. J Clin Endocrinol Metab. 1979 Aug;49(2):185–188. doi: 10.1210/jcem-49-2-185. [DOI] [PubMed] [Google Scholar]
  15. Gilman A. G. A protein binding assay for adenosine 3':5'-cyclic monophosphate. Proc Natl Acad Sci U S A. 1970 Sep;67(1):305–312. doi: 10.1073/pnas.67.1.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gray R. W., Wilz D. R., Caldas A. E., Lemann J., Jr The importance of phosphate in regulating plasma 1,25-(OH)2-vitamin D levels in humans: studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 1977 Aug;45(2):299–306. doi: 10.1210/jcem-45-2-299. [DOI] [PubMed] [Google Scholar]
  17. Haussler M. R., Baylink D. J., Hughes M. R., Brumbaugh P. F., Wergedal J. E., Shen F. H., Nielsen R. L., Counts S. J., Bursac K. M., McCain T. A. The assay of 1alpha,25-dihydroxyvitamin D3: physiologic and pathologic modulation of circulating hormone levels. Clin Endocrinol (Oxf) 1976;5 (Suppl):151S–165S. doi: 10.1111/j.1365-2265.1976.tb03823.x. [DOI] [PubMed] [Google Scholar]
  18. Heersche J. N., Heyboer M. P., Ng B. Hormone-specific suppression of adenosine 3',5'-monophosphate responses in bone in vitro during prolonged incubation with parathyroid hormone, prostaglandin E1, and calcitonin. Endocrinology. 1978 Aug;103(2):333–340. doi: 10.1210/endo-103-2-333. [DOI] [PubMed] [Google Scholar]
  19. Hill L. F., Davies M., Taylor C. M., Standbury S. W. Treatment of hypoparathyroidism with 1,25-dihydroxycholecalciferol. Clin Endocrinol (Oxf) 1976;5 (Suppl):167S–173S. doi: 10.1111/j.1365-2265.1976.tb03824.x. [DOI] [PubMed] [Google Scholar]
  20. Juan D., DeLUCA H. F. The regulation of 24,25-dihydroxyvitamin D3 production in cultures of monkey kidney cells. Endocrinology. 1977 Oct;101(4):1184–1193. doi: 10.1210/endo-101-4-1184. [DOI] [PubMed] [Google Scholar]
  21. KOLB F. O., STEINBACH H. L. Pseudohypoparathyroidism with secondary hyperparathyroidism and osteitis fibrosa. J Clin Endocrinol Metab. 1962 Jan;22:59–70. doi: 10.1210/jcem-22-1-59. [DOI] [PubMed] [Google Scholar]
  22. Kakuta S., Suda T., Sasaki S., Kimura N., Nagata N. Effects of parathyroid hormone on the accumulation of cyclic AMP in bone of vitamin D-deficient rats. Endocrinology. 1975 Nov;97(5):1288–1293. doi: 10.1210/endo-97-5-1288. [DOI] [PubMed] [Google Scholar]
  23. Kaplan R. A., Haussler M. R., Deftos L. J., Bone H., Pak C. Y. The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest. 1977 May;59(5):756–760. doi: 10.1172/JCI108696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kooh S. W., Fraser D., DeLuca H. F., Holick M. F., Belsey R. E., Clark M. B., Murray T. M. Treatment of hypoparathyroidism and pseudohypoparathyroidism with metabolites of vitamin D: evidence for impaired conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med. 1975 Oct 23;293(17):840–844. doi: 10.1056/NEJM197510232931702. [DOI] [PubMed] [Google Scholar]
  25. Lambert P. W., Syverson B. J., Arnaud C. D., Spelsberg T. C. Isolation and quantitation of endogenous vitamin D and its physiologically important metabolites in human plasma by high pressure liquid chromatography. J Steroid Biochem. 1977 Sep;8(9):929–937. doi: 10.1016/0022-4731(77)90189-3. [DOI] [PubMed] [Google Scholar]
  26. Lambert P. W., Toft D. O., Hodgson S. F., Lindmark E. A., Witrak B. J., Roos B. A. An improved method for the measurement of 1,25-(OH)2D3 in human plasma. Endocr Res Commun. 1978;5(4):293–310. doi: 10.1080/07435807809061094. [DOI] [PubMed] [Google Scholar]
  27. Lawoyin S., Norman D. A., Zerwekh J. E., Breslau N. A., Pak C. Y. A patient with pseudohypoparathyroidism with increased serum calcium and 1 alpha, 25-dihydroxyvitamin D after exogenous parathyroid hormone administration. J Clin Endocrinol Metab. 1979 Nov;49(5):783–786. doi: 10.1210/jcem-49-5-783. [DOI] [PubMed] [Google Scholar]
  28. Massry S. G., Tuma S., Dua S., Goldstein D. A. Reversal of skeletal resistance to parathyroid hormone in uremia by vitamin D metabolites: evidence for the requirement of 1,25(OH)2D3 and 24,25(OH)2D3. J Lab Clin Med. 1979 Jul;94(1):152–157. [PubMed] [Google Scholar]
  29. McDonald K. M. Responsiveness of bone to parathyroid extract in siblings with pseudohypoparathyroidism. Metabolism. 1972 Jun;21(6):521–531. doi: 10.1016/0026-0495(72)90096-0. [DOI] [PubMed] [Google Scholar]
  30. Metz S. A., Baylink D. J., Hughes M. R., Haussler M. R., Robertson R. P. Selective deficiency of 1,25-dihydroxycholecalciferol. A cause of isolated skeletal resistance to parathyroid hormone. N Engl J Med. 1977 Nov 17;297(20):1084–1090. doi: 10.1056/NEJM197711172972003. [DOI] [PubMed] [Google Scholar]
  31. Nusynowitz M. L., Klein M. H. Pseudoidiopathic hypoparathyroidism. Hypoparathyroidism with ineffective parathyroid hormone. Am J Med. 1973 Nov;55(5):677–686. doi: 10.1016/0002-9343(73)90191-5. [DOI] [PubMed] [Google Scholar]
  32. Rasmussen H., Wong M., Bikle D., Goodman D. B. Hormonal control of the renal conversion of 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol. J Clin Invest. 1972 Sep;51(9):2502–2504. doi: 10.1172/JCI107065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Russell R. G., Smith R., Walton R. J., Preston C., Basson R., Henderson R. G., Norman A. W. 1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism. Lancet. 1974 Jul 6;2(7871):14–17. doi: 10.1016/s0140-6736(74)91348-8. [DOI] [PubMed] [Google Scholar]
  34. Scriver C. R., Reade T. M., DeLuca H. F., Hamstra A. J. Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med. 1978 Nov 2;299(18):976–979. doi: 10.1056/NEJM197811022991803. [DOI] [PubMed] [Google Scholar]
  35. Sinha T. K., Allen D. O., Queener S. F., Bell N. H., Larson S., McClintock R. Effects of acetazolamide on the renal excretion of phosphate in hypoparathyroidism and pseudohypoparathyroidism. J Lab Clin Med. 1977 Jun;89(6):1188–1197. [PubMed] [Google Scholar]
  36. Sinha T. K., DeLuca H. F., Bell N. H. Evidence for a defect in the formation of 1alpha,25-dihydroxyvitamin D in pseudohypoparathyroidism. Metabolism. 1977 Jul;26(7):731–738. doi: 10.1016/0026-0495(77)90060-9. [DOI] [PubMed] [Google Scholar]
  37. Sinha T. K., Miller S., Feming J., Khairi R., Edmondson J., Johnston C. C., Jr, Bell N. H. Demonstration of a diurnal variation in serum parathyroid hormone in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab. 1975 Dec;41(06):1009–1013. doi: 10.1210/jcem-41-6-1009. [DOI] [PubMed] [Google Scholar]
  38. Taylor C. M., De Silva P., Hughes S. E. Competitive protein-binding assay for 24,25-dihydroxycholecalciferol. Calcif Tissue Res. 1977 May;22 (Suppl):40–44. doi: 10.1007/BF02064038. [DOI] [PubMed] [Google Scholar]
  39. Vaishava H., Rizvi S. N. Primary hyperparathyroidism associated with nutritional osteomalacia. Am J Med. 1969 Apr;46(4):640–644. doi: 10.1016/0002-9343(69)90083-7. [DOI] [PubMed] [Google Scholar]
  40. Wong G. L. Induction of metabolic changes and down regulation of bovine parathyroid hormone-responsive adenylate cyclase are dissociable in isolated osteoclastic and osteoblastic bone cells. J Biol Chem. 1979 Jan 10;254(1):34–37. [PubMed] [Google Scholar]
  41. Woodhouse N. J., Doyle F. H., Joplin G. F. Vitamin-D deficiency and primary hyperparathyroidism. Lancet. 1971 Aug 7;2(7719):283–286. doi: 10.1016/s0140-6736(71)91333-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES